Our scientific team will provide comprehensive information aligned with your laboratory research objectives.
Advanced Metabolic Peptide
CJC-1295 + Ipamorelin
- Supports investigation of dual-pathway GH axis modulation
- Enables analysis of receptor-specific endocrine signaling interactions
- Assists in studying pulsatile growth hormone release patterns
- Contributes to somatotropic and IGF-1 pathway research frameworks
- Facilitates deeper molecular understanding of coordinated secretagogue activity
Product Overview
CJC-1295 (a synthetic growth hormone–releasing hormone analogue) combined with Ipamorelin (a selective growth hormone secretagogue acting on GHS-R1a receptors) is investigated in laboratory research for its complementary modulation of the growth hormone axis. Within controlled experimental environments, this dual-peptide approach is commonly studied for coordinated receptor engagement and regulated endocrine signaling dynamics.
In research models, CJC-1295 is examined for its interaction with GHRH receptors influencing upstream growth hormone signaling, while Ipamorelin is studied for its selective activation of growth hormone secretagogue receptors. Together, this combination allows investigators to evaluate pulsatile GH modulation patterns, receptor-specific pathway activity, and downstream IGF-1–related intracellular signaling cascades.
At Nexzya Bioscience, both peptides are produced under strict research-grade manufacturing standards. Each batch undergoes comprehensive analytical validation to confirm molecular identity, structural precision, and purity specifications. Our quality assurance framework ensures consistency, traceability, and reproducibility across advanced endocrine and receptor-based laboratory investigations.
Key Characteristics
Combination of synthetic GHRH analogue (CJC-1295) and selective GHS-R1a agonist (Ipamorelin)
Designed for complementary receptor engagement in research models
Investigated in pulsatile growth hormone signaling studies
High-purity research-grade peptide formulations
Molecular identity verified through advanced chromatographic analysis
Studied for coordinated somatotropic axis modulation
Examined for receptor-specific intracellular signaling dynamics
Utilized in IGF-1 pathway and endocrine cascade research
Stable under recommended laboratory storage conditions
Batch-specific analytical documentation and traceability available
Direct Research Applications & Potential Benefits
Supports investigation of dual-pathway GH axis modulation
Enables analysis of receptor-specific endocrine signaling interactions
Assists in studying pulsatile growth hormone release patterns
Contributes to somatotropic and IGF-1 pathway research frameworks
Facilitates deeper molecular understanding of coordinated secretagogue activity
Final Overview
The CJC-1295 + Ipamorelin combination from Nexzya Bioscience reflects our commitment to precision peptide development and advanced research support. Manufactured exclusively for laboratory investigation, these compounds adhere to stringent purity and analytical validation standards to ensure reliable performance across endocrine research models.
For laboratories seeking analytically verified dual-secretagogue peptides for controlled somatotropic axis research, Nexzya Bioscience delivers research-grade solutions built on scientific rigor and consistency.
Request Technical Information
To receive detailed analytical reports, batch specifications, and technical documentation for the CJC-1295 + Ipamorelin combination, please complete the form below with your name and email.
Advanced Peptide Science & Biomolecular Research
South Korea — 대한민국
Czech Republic — Česká republika
Resources
NEXZYA™ Bioscience | Since 1986 All Rights Reserved